Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 4C4H5NO4.2K.Mg.4H |
| Molecular Weight | 630.8806 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H+].[H+].[H+].[H+].[Mg++].[K+].[K+].N[C@@H](CC([O-])=O)C([O-])=O.N[C@@H](CC([O-])=O)C([O-])=O.N[C@@H](CC([O-])=O)C([O-])=O.N[C@@H](CC([O-])=O)C([O-])=O
InChI
InChIKey=LVBRFZFUCKKGDJ-HJWRJIQTSA-J
InChI=1S/4C4H7NO4.2K.Mg/c4*5-2(4(8)9)1-3(6)7;;;/h4*2H,1,5H2,(H,6,7)(H,8,9);;;/q;;;;2*+1;+2/p-4/t4*2-;;;/m0000.../s1
| Molecular Formula | H |
| Molecular Weight | 1.0079 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C4H5NO4 |
| Molecular Weight | 131.0868 |
| Charge | -2 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | K |
| Molecular Weight | 39.0983 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | Mg |
| Molecular Weight | 24.305 |
| Charge | 2 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Potassium magnesium aspartate (K,Mg aspartate) is used in treating and preventing cardiac disruptions caused by electrolytic disturbances, primarily low potassium (K) and magnesium (Mg) levels (e.g. in the treatment with cardiac glycosides and diuretic drugs). It is used as a mineral supplement. The proposed mechanisms of action of magnesium-potassium aspartate include:
Stabilization of cellular membranes by normalization of the levels of magnesium and potassium in the cells.
Detoxification of ammonia or increase in the tricarboxylic acid-cycle flux. As increased levels of ammonia and depleted levels of potassium and magnesium ions in the plasma are associated with exercise-induced fatigue, this combination of aspartate (which detoxifies ammonia) and magnesium and potassium is particularly relevant in sports nutrition. Potassium magnesium aspartate is reported as an ingredient of Aspara in Japan, Panangin in Russian Federation, Bulgaria, China, Hungary, Romania etc., Asparkam in Georgia. Trophicard in Germany.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0046058 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | Panangin Approved UsePanangin is indicated for the treatment of:
post-myocardial infarction;
cardiac arrhythmia (in the complex therapy);
chronic heart disease;
treatment of cardiac glycosides (in the complex therapy);
replacement therapy with a deficiency of potassium / magnesium. |
|||
| Primary | Panangin Approved UsePanangin is indicated for the treatment of:
post-myocardial infarction;
cardiac arrhythmia (in the complex therapy);
chronic heart disease;
treatment of cardiac glycosides (in the complex therapy);
replacement therapy with a deficiency of potassium / magnesium. |
|||
| Primary | Panangin Approved UsePanangin is indicated for the treatment of:
post-myocardial infarction;
cardiac arrhythmia (in the complex therapy);
chronic heart disease;
treatment of cardiac glycosides (in the complex therapy);
replacement therapy with a deficiency of potassium / magnesium. |
|||
| Primary | Panangin Approved UsePanangin is indicated for the treatment of:
post-myocardial infarction;
cardiac arrhythmia (in the complex therapy);
chronic heart disease;
treatment of cardiac glycosides (in the complex therapy);
replacement therapy with a deficiency of potassium / magnesium. |
Sample Use Guides
Take 1-2 tablets three times a day, but not more than 3 tablets per reception after a meal, because fasting gastric contents reduces the effectiveness of the drug. Duration of application and the need for repeated applications are defined individually.
Injections
Applied intravenous drip infusion in a slow injection (~ 20 drops of 1 minute) of 1-2 ampoules of drug is dissolved in 50-100 ml glucose solution or 5% dextrose. Reintroducing - no earlier than 4-6 hours after the first drip.
main substances (1 tablet and 1 vial, respectively):
166,3 mg of potassium aspartate;
175 mg of magnesium aspartate.
452 mg of potassium aspartate;
400 mg of magnesium aspartate.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:09:31 UTC 2023
by
admin
on
Sat Dec 16 07:09:31 UTC 2023
|
| Record UNII |
55TUI7Q42I
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB14987MIG
Created by
admin on Sat Dec 16 07:09:31 UTC 2023 , Edited by admin on Sat Dec 16 07:09:31 UTC 2023
|
PRIMARY | |||
|
55TUI7Q42I
Created by
admin on Sat Dec 16 07:09:31 UTC 2023 , Edited by admin on Sat Dec 16 07:09:31 UTC 2023
|
PRIMARY | |||
|
71311552
Created by
admin on Sat Dec 16 07:09:31 UTC 2023 , Edited by admin on Sat Dec 16 07:09:31 UTC 2023
|
PRIMARY | |||
|
14842-81-0
Created by
admin on Sat Dec 16 07:09:31 UTC 2023 , Edited by admin on Sat Dec 16 07:09:31 UTC 2023
|
PRIMARY | |||
|
1793925
Created by
admin on Sat Dec 16 07:09:31 UTC 2023 , Edited by admin on Sat Dec 16 07:09:31 UTC 2023
|
PRIMARY | |||
|
55TUI7Q42I
Created by
admin on Sat Dec 16 07:09:31 UTC 2023 , Edited by admin on Sat Dec 16 07:09:31 UTC 2023
|
PRIMARY | |||
|
100000078842
Created by
admin on Sat Dec 16 07:09:31 UTC 2023 , Edited by admin on Sat Dec 16 07:09:31 UTC 2023
|
PRIMARY |